by Backoffice | Jan 23, 2024 | Collaborations
Cell2Cure has January 2024 received a significant equity investment from Endeavour Cell ApS, to further develop our collaboration. Endeavour Cells will own 51% of the company. In addition to the invested capital the collaboration with Endeavor Cells includes milestone...
by Backoffice | Jan 4, 2024 | Collaborations
In Europe, approximately 30 million people suffer from blindness and visual impairment. Rare Eye Diseases are a major cause that can result in blindness in children and young adults and affect adults and the ageing population. Current management is expensive, has low...
by Backoffice | May 25, 2023 | Collaborations
Cell2Cure has developed a stem cell product that does not require a tissue match between donor and patient and can simply be stored in the freezer for use in various clinical purposes. Cell2Cure was in continuation of the pres release visited – and researched...
by Backoffice | Feb 27, 2022 | Collaborations
Cell2Cure has entered into a collaboration agreement with Endeavour Cells ApS, to collaborate on the preparation, conduct, management, and completion of an un-blinded phase I/II clinical trial in children with autism. The clinical trial title is “Effect of adipose...
by Backoffice | Feb 12, 2022 | Collaborations
Cell2Cure has entered into a sublicense agreement with Endeavour Cells ApS, which will allow Endeavour Cells ApS to develop, manufacture and commercialize ASCs for the treatment of Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD),...
by Backoffice | Jul 10, 2021 | Collaborations
Cell2Cure (C2C) has entered into a collaboration agreement with Cbio A/S to establish C2C´s own GMP facility for production of adipose tissue-derived mesenchymal stromal cell products (ASCs) in Cbio´s newly established and approved cell production facility,...
